Skip to main content
Top
Published in: Clinical and Experimental Nephrology 5/2009

01-10-2009 | Original Article

Anemia and hypertension are risk factors for both renal prognosis and survival in patients with diabetes mellitus

Authors: Yoshie Sasatomi, Hidetoshi Kaneoka, Yasuhiro Abe, Atunori Ishimura, Satoru Ogahara, Toshiaki Murata, Noriko Uesugi, Shigeo Takebayashi, Hiroshi Iwasaki, Takao Saito

Published in: Clinical and Experimental Nephrology | Issue 5/2009

Login to get access

Abstract

Background

Diabetic nephrosclerosis is the most common cause of renal failure in the industrialized countries. At the same time, the mortality rate of patients with diabetes mellitus is high.

Methods

To clarify the factors influencing the prognosis and survival of patients with diabetic nephrosclerosis, we carried out a retrospective follow-up study of 166 cases (age, 55.6 ± 1.0 years; male/female, 110/56) by simple and multifactorial analyses of clinical data recorded at time of renal biopsy, including survival after diagnosis of diabetic mellitus (months), body mass index (BMI) (kg/m2) [body weight/(body height)2], age (years), mean blood pressure (mBP) (mmHg) [diastolic BP + (systolic BP − diastolic BP)/3], serum levels of albumin (mg/dl), urea nitrogen (BUN) (mg/dl), serum creatinine (s-Cr) (mg/dl), total cholesterol (mg/dl), triglyceride (mg/dl), and fasting blood sugar (FBS) (mg/dl), hematocrit (%), HbA1c (%), urinary protein secretion (g/day), insulin resistance, BP control (good, <140/90 mmHg or poor, ≥140/90 mmHg) after biopsies, and pathomorphological parameters at the biopsy.

Results

We found a significant association between renal prognosis and several factors, e.g., hypoalbuminemia, anemia, high levels of BUN and s-Cr, hypercholesteremia, hypertriglyceridemia at biopsy, poor control of BP after biopsies, Kimmelstiel–Wilson nodule, and severe glomerular and tubulointerstitial damages at the biopsy. In addition, associations between survival and factors such as low value of BMI, elderly age at the biopsy, and poor control of BP after biopsies were significant. By multivariate analysis we also found a significant association of renal prognosis with anemia, BUN, severe glomerular damage at the biopsy, and poor control of BP after biopsies. At the same time, poor control of BP after biopsies had a significant association with survival. On Kaplan–Meier analysis, anemia at biopsy and hypertension after biopsies are risk factors for both renal prognosis and survival in diabetes mellitus patients.

Conclusions

Our data strongly suggest that good control of BP after biopsies and anemia at the biopsy play pivotal roles in the prognosis and survival of patients with diabetic glomerulosclerosis.
Literature
1.
go back to reference The statistic analyzed commission of Japan Society for Dialysis therapy: an overview of dialysis treatment in Japan (as of December 31, 2002). The statistic analyzed commission of Japan Society for Dialysis therapy: an overview of dialysis treatment in Japan (as of December 31, 2002).
2.
go back to reference Bertoni AG, Kirk JK, Goff DC Jr, Wagenknecht LE. Excess mortality related to diabetes mellitus in elderly Medicare beneficiaries. Ann Epidemiol. 2004;14(5):362–7.CrossRefPubMed Bertoni AG, Kirk JK, Goff DC Jr, Wagenknecht LE. Excess mortality related to diabetes mellitus in elderly Medicare beneficiaries. Ann Epidemiol. 2004;14(5):362–7.CrossRefPubMed
3.
go back to reference De Groote P, Lamblin N, Mouquet F, Plichon D, Mcfadden E, Van Belle E, et al. Impact of diabetes mellitus on long-term survival in patients with congestive heart failure. Eur heart J. 2004;25(8):656–62.CrossRefPubMed De Groote P, Lamblin N, Mouquet F, Plichon D, Mcfadden E, Van Belle E, et al. Impact of diabetes mellitus on long-term survival in patients with congestive heart failure. Eur heart J. 2004;25(8):656–62.CrossRefPubMed
4.
go back to reference Otter W, Kleybrink s, Doering W, Standl E, Schnell O. Hospital outcome of acute myocardial infarction in patients with and without diabetes mellitus. Diabet Med. 2004;21(2):183–7.CrossRefPubMed Otter W, Kleybrink s, Doering W, Standl E, Schnell O. Hospital outcome of acute myocardial infarction in patients with and without diabetes mellitus. Diabet Med. 2004;21(2):183–7.CrossRefPubMed
5.
go back to reference Hoffart N, Nissenson AR. The future of end-stage renal disease care: nephrology enters a new millennium. Adv Ren Replace Ther. 1988;5:257–66.CrossRef Hoffart N, Nissenson AR. The future of end-stage renal disease care: nephrology enters a new millennium. Adv Ren Replace Ther. 1988;5:257–66.CrossRef
6.
go back to reference Lee H, Manns B, Taub K, Ghali WA, Dean S, Johnson D, et al. Cost analysis of ongoing care of patients with end stage renal disease: the impact of dialysis modality and dialysis access. Am J Kidney Dis. 2002;40:611–22.CrossRefPubMed Lee H, Manns B, Taub K, Ghali WA, Dean S, Johnson D, et al. Cost analysis of ongoing care of patients with end stage renal disease: the impact of dialysis modality and dialysis access. Am J Kidney Dis. 2002;40:611–22.CrossRefPubMed
7.
go back to reference Ohkubo Y, Kishikawa H, Araki E, Miyata T, Isami S, Motoyoshi S, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: randamized prospective 6-year study. Diabetes Res Clin Pract. 1995;28:103–17.CrossRefPubMed Ohkubo Y, Kishikawa H, Araki E, Miyata T, Isami S, Motoyoshi S, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: randamized prospective 6-year study. Diabetes Res Clin Pract. 1995;28:103–17.CrossRefPubMed
8.
go back to reference Fioretto P, Steffes MW, Sutherland DE, Goetz FC, Mauer M. Reversal of lesions of diabetic nephropathy after pancreas transplantation. N Engl J Med. 1998;339:69–75.CrossRefPubMed Fioretto P, Steffes MW, Sutherland DE, Goetz FC, Mauer M. Reversal of lesions of diabetic nephropathy after pancreas transplantation. N Engl J Med. 1998;339:69–75.CrossRefPubMed
9.
go back to reference Hovind P, Rossing P, Tarnow L, Smidt UM, Parving HH. Remission and regression in the nephropathy of type 1 diabetes when blood pressure is controlled aggressively. Kidney Int. 2001;60:277–83.CrossRefPubMed Hovind P, Rossing P, Tarnow L, Smidt UM, Parving HH. Remission and regression in the nephropathy of type 1 diabetes when blood pressure is controlled aggressively. Kidney Int. 2001;60:277–83.CrossRefPubMed
10.
go back to reference American Diabetes Association: treatment of hypertension in adults with diabetes. Diabetes Care. 2002;25(Suppl 1):S71–S73. American Diabetes Association: treatment of hypertension in adults with diabetes. Diabetes Care. 2002;25(Suppl 1):S71–S73.
11.
go back to reference Inomata S, Itoh M, Imai H, Sato T. Serum levels of erythropoietin as a novel marker reflecting the severity of diabetic nephropathy. Nephron. 1997;75:426–30.CrossRefPubMed Inomata S, Itoh M, Imai H, Sato T. Serum levels of erythropoietin as a novel marker reflecting the severity of diabetic nephropathy. Nephron. 1997;75:426–30.CrossRefPubMed
12.
go back to reference Keane WF, Brenner BM, de Zeeuw D, Grunfeld JP, McGill J, Mitch WE, et al. The risk of developing end stage renal disease in patients with type 2 diabetes and nephropathy: the RENAAL Study. Kidney Int. 2003;63:1499–507.CrossRefPubMed Keane WF, Brenner BM, de Zeeuw D, Grunfeld JP, McGill J, Mitch WE, et al. The risk of developing end stage renal disease in patients with type 2 diabetes and nephropathy: the RENAAL Study. Kidney Int. 2003;63:1499–507.CrossRefPubMed
13.
go back to reference Hansen HP, Tauber-Lassen E, Jensen BR, Parving HH. Effect of dietary protein restriction on prognosis in patients with diabetic nephropathy. Kidney Int. 2002;62(1):202–28.CrossRef Hansen HP, Tauber-Lassen E, Jensen BR, Parving HH. Effect of dietary protein restriction on prognosis in patients with diabetic nephropathy. Kidney Int. 2002;62(1):202–28.CrossRef
14.
go back to reference Remuzzi G, Schieppati A, Ruggenenti P. Nephropathy in patients with type 2 diabetes. N Engl J Med. 2002;346:1145–51.CrossRefPubMed Remuzzi G, Schieppati A, Ruggenenti P. Nephropathy in patients with type 2 diabetes. N Engl J Med. 2002;346:1145–51.CrossRefPubMed
15.
go back to reference Narita T, Koshimura J, Suzuki K, Murata M, Meguro H, Fujita H, et al. Effects of short-term glycemic control, low protein diet and administration of enalapril on renal hemodynamics and protein permselectivity in type 2 diabetic patients with microalbuminuria. Tohoku J Exp Med. 1999;189(2):117–33.CrossRefPubMed Narita T, Koshimura J, Suzuki K, Murata M, Meguro H, Fujita H, et al. Effects of short-term glycemic control, low protein diet and administration of enalapril on renal hemodynamics and protein permselectivity in type 2 diabetic patients with microalbuminuria. Tohoku J Exp Med. 1999;189(2):117–33.CrossRefPubMed
16.
go back to reference Shestakova MV, Chugunova LA, Shamkhalova MSh, Dirochka IuA, Dedov II. Diabetic nephropathy: risk factors of rapid progression of renal failure. Ter Arkh. 1999;71(6):45–9.PubMed Shestakova MV, Chugunova LA, Shamkhalova MSh, Dirochka IuA, Dedov II. Diabetic nephropathy: risk factors of rapid progression of renal failure. Ter Arkh. 1999;71(6):45–9.PubMed
17.
go back to reference Furuta T, Saito T, Ootaka T, Soma J, Obara K, Abe K, et al. The role of macrophages in diabetic glomerulosclerosis. AJKD. 1993;21:480–5.CrossRefPubMed Furuta T, Saito T, Ootaka T, Soma J, Obara K, Abe K, et al. The role of macrophages in diabetic glomerulosclerosis. AJKD. 1993;21:480–5.CrossRefPubMed
18.
go back to reference Gellman DD, Dirani DL, Soothill JF, Muehrcke RC, Kark RM. Diabetic nephropathy: a clinical and pathologic study based on renal biopsies. Medicine. 1959;38:321–67.CrossRefPubMed Gellman DD, Dirani DL, Soothill JF, Muehrcke RC, Kark RM. Diabetic nephropathy: a clinical and pathologic study based on renal biopsies. Medicine. 1959;38:321–67.CrossRefPubMed
19.
go back to reference Sasatomi Y, Sato H, Chiba Y, Abe Y, Takeda S, Ogahara S, et al. Prognostic factors for renal amyloidosis: a clinicopathological study using cluster analysis. Int Med. 2007;46:213–219.CrossRef Sasatomi Y, Sato H, Chiba Y, Abe Y, Takeda S, Ogahara S, et al. Prognostic factors for renal amyloidosis: a clinicopathological study using cluster analysis. Int Med. 2007;46:213–219.CrossRef
20.
go back to reference UK prospective Diabetes study Group: tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ. 1998; 317:703–713. UK prospective Diabetes study Group: tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ. 1998; 317:703–713.
21.
go back to reference Heart Outcomes Prevention Evaluation (HOPE) study investigators: effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000;355:253–259.CrossRef Heart Outcomes Prevention Evaluation (HOPE) study investigators: effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000;355:253–259.CrossRef
22.
go back to reference Hansson L, Zanchetti A, Carruthers SG, Dahlof B, Elmfeldt D, Julius S, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the hypertension optimal treatment (HOT) randomised trial. HOT Study Group. Lancet. 1998;351:1755–62.CrossRefPubMed Hansson L, Zanchetti A, Carruthers SG, Dahlof B, Elmfeldt D, Julius S, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the hypertension optimal treatment (HOT) randomised trial. HOT Study Group. Lancet. 1998;351:1755–62.CrossRefPubMed
23.
go back to reference Hunsicker LG, Adler S, Caggiula A, England BK, Greene T, Kusek JW, et al. Predictors of the progression of renal disease study. Kidney Int. 1997;51:1908–19.CrossRefPubMed Hunsicker LG, Adler S, Caggiula A, England BK, Greene T, Kusek JW, et al. Predictors of the progression of renal disease study. Kidney Int. 1997;51:1908–19.CrossRefPubMed
24.
go back to reference Samuelsson O. Complex apolipoprotein-B containing lipoprotein particles are associated with a high rate of progression of human progressive renal insufficiency. J Am Soc Nephrol. 1998;9:1482–8.PubMed Samuelsson O. Complex apolipoprotein-B containing lipoprotein particles are associated with a high rate of progression of human progressive renal insufficiency. J Am Soc Nephrol. 1998;9:1482–8.PubMed
25.
go back to reference Tozawa M, Iseki K, Iseki C, Oshiro S, Ikemiya Y, Takishita S. Triglyceride, but not total cholesterol or low-density lipoprotein cholesterol levels, predict development of proteinuria. Kidney Int. 2002;62(5):1743–9.CrossRefPubMed Tozawa M, Iseki K, Iseki C, Oshiro S, Ikemiya Y, Takishita S. Triglyceride, but not total cholesterol or low-density lipoprotein cholesterol levels, predict development of proteinuria. Kidney Int. 2002;62(5):1743–9.CrossRefPubMed
26.
go back to reference Mulec H, Johnsen SA, Wiklund O, Bjorck S. Cholesterol: a renal risk factor in diabetic nephropathy? Am J Kidney Dis. 1993;22(1):196–201.CrossRefPubMed Mulec H, Johnsen SA, Wiklund O, Bjorck S. Cholesterol: a renal risk factor in diabetic nephropathy? Am J Kidney Dis. 1993;22(1):196–201.CrossRefPubMed
27.
go back to reference Ellis D, Lloyd C, Becker DJ, Forrest KY, Orchard TJ. The changing course of diabetic nephropathy: low density lipoprotein cholesterol and blood pressure correlate with regression of proteinuria. Am J Kidney Dis. 1996;27:809–18.CrossRefPubMed Ellis D, Lloyd C, Becker DJ, Forrest KY, Orchard TJ. The changing course of diabetic nephropathy: low density lipoprotein cholesterol and blood pressure correlate with regression of proteinuria. Am J Kidney Dis. 1996;27:809–18.CrossRefPubMed
28.
go back to reference Olefsky JM, Farquhar JW, Reaven GM. Reappraisal of the role of insulin in hypertriglyceridemia. AM J Med. 1974;57:551–60.CrossRefPubMed Olefsky JM, Farquhar JW, Reaven GM. Reappraisal of the role of insulin in hypertriglyceridemia. AM J Med. 1974;57:551–60.CrossRefPubMed
29.
go back to reference Pollar T, Vessby B, Lithell H. Lipoprotein lipase activity in skeletal muscle is related to insulin sensitivity. Arterioscler Thromb. 1991;11:1192–203.CrossRef Pollar T, Vessby B, Lithell H. Lipoprotein lipase activity in skeletal muscle is related to insulin sensitivity. Arterioscler Thromb. 1991;11:1192–203.CrossRef
30.
go back to reference Yildiz A, Hursit M, Celik AV, Kayacan SM, Yazici H, Akkaya V, et al. Doxazosin, but not amlodipine decreases insulin resistance in patients with chronic renal failure: a prospective, randomized-controlled study. Clin Nephrol. 2002;58(6):405–10.CrossRefPubMed Yildiz A, Hursit M, Celik AV, Kayacan SM, Yazici H, Akkaya V, et al. Doxazosin, but not amlodipine decreases insulin resistance in patients with chronic renal failure: a prospective, randomized-controlled study. Clin Nephrol. 2002;58(6):405–10.CrossRefPubMed
31.
go back to reference Harada N, Takishita E, Ishimura N, Minami A, Sakamoto S, Nakaya Y. Combined effect of ACE inhibitor and exercise training on insulin resistance In type 2 diabetic rats. Life Sci. 2002;70(15):1811–20.CrossRefPubMed Harada N, Takishita E, Ishimura N, Minami A, Sakamoto S, Nakaya Y. Combined effect of ACE inhibitor and exercise training on insulin resistance In type 2 diabetic rats. Life Sci. 2002;70(15):1811–20.CrossRefPubMed
32.
go back to reference Suzuki Y, Ueno M, Hayashi H, Nishi S, Satou H, Karasawa R, et al. A light microscopic study of glomerulosclerosis in Japanese patients with noninsulin-dependent diabetes mellitus: the relationship between clinical and histological features. Clin Nephrol. 1994;42(3):155–62.PubMed Suzuki Y, Ueno M, Hayashi H, Nishi S, Satou H, Karasawa R, et al. A light microscopic study of glomerulosclerosis in Japanese patients with noninsulin-dependent diabetes mellitus: the relationship between clinical and histological features. Clin Nephrol. 1994;42(3):155–62.PubMed
33.
go back to reference Yun YS, Lee HC, Yoo NC, Song YD, Lim SK, Kim KR, et al. Reduced erythropoietin responsiveness to anemia in diabetic patients before advanced diabetic nephropathy. Diabetes Res Clin Pract. 1999;46:223–9.CrossRefPubMed Yun YS, Lee HC, Yoo NC, Song YD, Lim SK, Kim KR, et al. Reduced erythropoietin responsiveness to anemia in diabetic patients before advanced diabetic nephropathy. Diabetes Res Clin Pract. 1999;46:223–9.CrossRefPubMed
34.
go back to reference Bosman DR, Winkler AS, Marsden JT, Macdougall IC, Watkins PJ. Anemia with erythropoietin deficiency occurs early in diabetic nephropathy. Diabetes Care. 2001;24:495–9.CrossRefPubMed Bosman DR, Winkler AS, Marsden JT, Macdougall IC, Watkins PJ. Anemia with erythropoietin deficiency occurs early in diabetic nephropathy. Diabetes Care. 2001;24:495–9.CrossRefPubMed
35.
go back to reference Winkler AS, Marsden J, Chaudhuri KR, Mambley H, Watkins PJ. Erythropoietin depletion and anemia in diabetes mellitus. Diabet Med. 1999;16:813–9.CrossRefPubMed Winkler AS, Marsden J, Chaudhuri KR, Mambley H, Watkins PJ. Erythropoietin depletion and anemia in diabetes mellitus. Diabet Med. 1999;16:813–9.CrossRefPubMed
36.
go back to reference Bayes B, Serra A, Junca J, Lauzurica R. Successful treatment of anemia of nephrotic syndrome with recombinant human erythropoietin. Nephrol Dial Transplant. 1998;13:1894–5.CrossRefPubMed Bayes B, Serra A, Junca J, Lauzurica R. Successful treatment of anemia of nephrotic syndrome with recombinant human erythropoietin. Nephrol Dial Transplant. 1998;13:1894–5.CrossRefPubMed
37.
go back to reference Laffel LM, McGill JB, Ganx DJ. The beneficial effect of angiotensin-converting enzyme inhibition with captopril on diabetic nephropathy in normotensive IDDM patients with microalbuminuria. Am J Med. 1995;99:497–504.CrossRefPubMed Laffel LM, McGill JB, Ganx DJ. The beneficial effect of angiotensin-converting enzyme inhibition with captopril on diabetic nephropathy in normotensive IDDM patients with microalbuminuria. Am J Med. 1995;99:497–504.CrossRefPubMed
38.
go back to reference The microalbuminuria Captopril Study Group: captopril reduces the risk of nephropathy in IDDM patients with microalbuminuria. Diabetologia. 1996;39:587–593.CrossRef The microalbuminuria Captopril Study Group: captopril reduces the risk of nephropathy in IDDM patients with microalbuminuria. Diabetologia. 1996;39:587–593.CrossRef
39.
go back to reference Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med. 1993;329:1456–62.CrossRefPubMed Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med. 1993;329:1456–62.CrossRefPubMed
40.
go back to reference Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med. 2001;345:870–8.CrossRefPubMed Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med. 2001;345:870–8.CrossRefPubMed
41.
go back to reference Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345:851–60.CrossRefPubMed Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345:851–60.CrossRefPubMed
42.
go back to reference Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345:861–9.CrossRefPubMed Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345:861–9.CrossRefPubMed
43.
go back to reference Locatelli F, Pisoni RL, Combe C, Bommer J, Andreucci VE, Piera L, et al. Anemia in haemodialysis patients of five European countries: association with morbidity and mortality in the Dialysis Outcomes and Practice Patterns study (DOPPS). Nephrol dial Transplant. 2004;19:121–32.CrossRefPubMed Locatelli F, Pisoni RL, Combe C, Bommer J, Andreucci VE, Piera L, et al. Anemia in haemodialysis patients of five European countries: association with morbidity and mortality in the Dialysis Outcomes and Practice Patterns study (DOPPS). Nephrol dial Transplant. 2004;19:121–32.CrossRefPubMed
44.
go back to reference Licatelli F, Pisoni RL, Bragg JL. Higher hemoglobin levels are associated with lower rates of mortality and hospitalization among European hemodialysis patients: results from the DOPPS. Nephrol Dial Transplant. 2002;17(S-1):23. Licatelli F, Pisoni RL, Bragg JL. Higher hemoglobin levels are associated with lower rates of mortality and hospitalization among European hemodialysis patients: results from the DOPPS. Nephrol Dial Transplant. 2002;17(S-1):23.
45.
go back to reference UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837–53.CrossRef UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837–53.CrossRef
Metadata
Title
Anemia and hypertension are risk factors for both renal prognosis and survival in patients with diabetes mellitus
Authors
Yoshie Sasatomi
Hidetoshi Kaneoka
Yasuhiro Abe
Atunori Ishimura
Satoru Ogahara
Toshiaki Murata
Noriko Uesugi
Shigeo Takebayashi
Hiroshi Iwasaki
Takao Saito
Publication date
01-10-2009
Publisher
Springer Japan
Published in
Clinical and Experimental Nephrology / Issue 5/2009
Print ISSN: 1342-1751
Electronic ISSN: 1437-7799
DOI
https://doi.org/10.1007/s10157-009-0191-5

Other articles of this Issue 5/2009

Clinical and Experimental Nephrology 5/2009 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.